# Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation

> **NCT03402776** · PHASE3 · UNKNOWN · sponsor: **University Hospital, Grenoble** · enrollment: 200 (estimated)

## Conditions studied

- Haemopoietic Stem Cell Transplantation
- Allograft

## Interventions

- **DRUG:** 4th dose of hexavalent vaccine 1 month after the 3rd dose

## Key facts

- **NCT ID:** NCT03402776
- **Lead sponsor:** University Hospital, Grenoble
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-01
- **Primary completion:** 2020-05-31
- **Final completion:** 2021-05-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2018-06-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402776, "Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03402776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*